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IMPROVED TARGET COVERAGE OF SPINAL METASTASES THROUGH THE
USE OF FLATTENING FILTER FREE BEAMS

Laura Christine Bennett, B.S.
Advisory Professor: Oleg Vassiliev, Ph.D.

Of the patients that are diagnosed with metastatic disease, up to 40% will
develop vertebral osseous metastases. These metastases tend to be located in close
proximity to the spinal cord itself, making it difficult to achieve the recommended
minimum dose of 14 Gy for single fraction SBRT or 21 Gy1 for three fraction SBRT
while maintaining acceptable doses to the cord and cauda equina. This proximity of the
target to critical structures has the potential to compromise the efficacy of the radiation
treatment plan in favor of reducing normal tissue dose, resulting in poor local control and
tumor recurrence at follow-up. Flattening Filter Free (FFF) photon beams have been
shown to have lower out-of-field dose and sharper dose gradients when compared with
conventionally flattened (FF) photon beams of similar energy; this sharp dose fall-off
could potentially prove beneficial in cases where greater precision is required, such as
for high-dose hypofractionated radiation treatments of vertebral metasases. The purpose
of this project was to compare the physical properties, namely penumbral width and
penumbral and out-of-field dose of FFF and FF photon beams as well as determine the
clinical effects of these beams on vertebral osseous tumors. It was hypothesized that FFF
beams would show a definitive improvement in target coverage while maintaining
acceptable normal tissue doses when compared with FF beams. To test this hypothesis,
penumbral width and dose were measured for FF and FFF beam profiles at various
iv

depths and field sizes using the Varian Standard Beam Data by examining the treatment
plans for twelve patients with spine metastases using both FF and FFF beams. There was
a statistically significant reduction in penumbral width for FFF plans when compared to
FF plans; however, this difference was in effect quite small and may not translate into
better treatment plans. There was no demonstrable difference between treatment plans
developed using FF or FFF beams in terms of minimum dose to the GTV. However,
there was significant reduction in treatment delivery time for FFF plans, which may lead
to reduced intrafractional variation from patient motion and a more positive patient
experience.
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1 INTRODUCTION
1.1 – Spine Metastases
1.1.1 – Prevalence of Spine Metastases
Of all patients that are diagnosed with metastatic cancer each year, it is
estimated that 40% will develop metastases in the spinal column, and of those who
eventually die due to cancer, up to 70% will have spinal metastases at the time of death2–
5

. Often, these patients may experience pain, incontinence, or loss of ambulatory

function due to compression of the spine – a complication that occurs in up to 20% of
patients with spine metastases6. The recommended treatment in these cases is often a
combination of therapies including surgical resection of the tumor and radiation
therapy7.
1.1.2 – Standard Treatments and Typical Patient Outcomes
Patients undergoing radiotherapy for spinal cord lesions either adjuvant with
surgery or as a stand-alone treatment often receive stereotactic body radiation therapy
(SBRT). Standard fractionation external-beam radiotherapy (EBRT) is typically
scheduled as 1.8-2.0 Gy delivered 5 days per week for up to 8 weeks8. In comparison,
SBRT treatments typically include prescriptions doses of 24-30 Gy over a course of 1-5
fractions9. This is most often the preferred method of radiation therapy due to the
sensitivity of the spinal cord to radiation and the proximity of the tumor to the cord
itself; in such cases, hypofractionated, high dose radiation is favored in order to limit
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normal tissue dose while delivering adequate radiation to the target. In order to
minimize dose to healthy tissue (spine, lungs, kidney, etc.) while maintaining target
coverage and prescription dose constraints, a large number of convergent beams are
directed at the target to maximize dose around the gross tumor volume (GTV)10. In most
cases, some sort of immobilization device such as a vac-loc bag or thermoplastic cast is
used to limit intrafractional motion during treatment11. Additionally, image-guided
tracking in the form of a combination of CT and MRI is used in almost all cases to limit
intrafractional motion during treatment11,12.
Outcomes for patients undergoing SBRT for spinal metastases are typically
positive. A study by Zelefsky et al13 in 1992 examining patients undergoing radiation
treatment of the spine reported that 92% who completed treatment experienced pain
relief; another study by Yamada et al14 examining high-dose hypofractionated IMRT for
spinal metastasis in 93 patients showed 90% local control at 15 months post therapy.
Ahmed et al15 treated eighty-five spinal lesions using SBRT; local control at 12 months
was 83.3% and 91.2% for patients with and without prior radiotherapy respectively.
Local control is more likely for these patients when a minimum “threshold dose”
is met in the GTV; an investigation of 285 patients with spinal metastases treated with
SBRT by Bishop et al found that local control was more likely with higher GTV
minimum dose (Dmin) and recommended that patients undergoing a single fraction
course receive at least 14 Gy to the GTV Dmin while those undergoing a three fraction
course should receive at least 21 Gy to the GTV Dmin1. Unfortunately, spine metastases
are often located close to the cord itself –often within a millimeter or less - making it
difficult to meet the thresholds necessary to establish tumor local control without
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imparting excessive dose to the cord or cauda equina16,17. Due to the risk of permanent
radiation myelopathy, many physicians may be forced to limit dose to the GTV in order
to maintain clinically acceptable doses to the cord, reducing the overall efficacy of
treatment18.

1.2 – Flattening Filter Free Beams
1.2.1 – Characteristics of Flattening Filter Free Beams
In recent years, manufacturers of medical linear accelerators (linacs) have
begun to produce machines capable of producing beams in Flattening Filter Free (FFF)
mode. Traditionally, photon beams use a metal flattening filter (FF) in order to produce
dose profiles with uniform photon intensity across the field; FFF beams are the result of
removing the flattening filter, creating a more “peaked” dose distribution19,20. FFF beams
were originally conceived for use with fluence-modifying devices such as multi-leaf
collimators for IMRT, where smaller average field sizes make a large, uniform dose
distribution unnecessary21.
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Figure 1-1: Profiles for FFF (red) and FF (blue) beams; FFF profile is noticeably more "peaked"

Compared to traditionally flattened beams, FFF beams have a number of
unique characteristics, the first and most obvious being the singular shape of their dose
distributions: unlike FF beams, FFF beams are marked by high fluence in the center of
the field with steep fall-off at the field edges22. The sharper dose gradient is likely a
function of the demonstrated reduction in head scatter, electron contamination, and
overall out-of-field dose common to FFF beams due to elimination of the filter23–25. An
additional benefit of FFF beams is their ability to deliver the same prescription as FF
beams at a significantly higher dose rate, allowing beam-on time to be greatly
reduced26,27 while reducing the amount of scatter generated. The resultant reduction in
treatment time is highly beneficial for treatments wherein high precision is essential, as it
limits the potential for intrafractional motion to create unacceptable errors28,29.\
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1.2.2 – Biology and Physics of Flattening Filter Free Beams
There is a reasonable biological component as to why FFF should be
considered over FF beams: to begin with, the softer energy spectrum of FFF may result
in a higher relative biological effectiveness (RBE). A traditional FF beam has a much
harder spectra due to the selective removal of lower energy photons by the flattening
filter. This results in a beam that is more penetrating, but has a lower linear energy
transfer (LET). A softer beam produces lower energy electrons in the medium, resulting
in a higher LET and therefore a higher RBE30. Additionally, the increased dose rate of
FFF beams may have an effect on tumor cell survival. Radiosensitivity is reduced at low
dose rates, as intracellular repair may begin to take place for longer treatment times, as
the half-time for repair may be less than one hour31.
For vertebral osseous tumors, energy deposition varies with respect to other
types of tissue (muscle, fat). Bone has a higher average atomic number than normal
tissues at 12.31 kg/m3 versus 7.64 kg/m3 for muscle, 6.46 kg/m3 for fat, or 7.51 kg/m3
for water32. At lower energies, this results in a higher probability for interaction via the
photoelectric effect which has a high Z dependence, resulting in greater dose
deposition in bone. However, this is more of a concern at diagnostic energies (30-150
keV) than therapeutic energies (6-18 MeV), as the cross section of the photoelectric
effect is inversely proportional to photon energy. Instead, the Compton effect
predominates at therapeutic energy levels and effectively determines dose in this
range. Unlike the photoelectric effect, which has a strong dependence on the Z of the
material, the Compton effect is primarily dependent on electron density. Bone, having
a lower electron density than water (3.192 x 1026 elect/kg versus 3.343 x 1026
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elect/kg), is subject to fewer Compton interactions and thus has slightly lower energy
deposition than other tissues32.
Physically, the removal of the flattening filter is associated with a reduction in
out-of-field dose. This is primarily a function of the elimination of the flattening filter
as a source of scatter23 as well as the improvement in delivery efficiency resulting in
reduced head leakage22.

1.2.3 – Prior Studies
There are a number of extant studies that have investigated the physical
properties of FFF beams as well as their clinical implications. A research group at MD
Anderson Cancer Center published three studies in 2006 examining the dosimetric
properties of FFF beams; backscatter, depth dose profiles, lateral dose profiles, MLC
leakage, total scatter factor, and dose rate were investigated and compared with
conventional FF beams33–35. In later studies by Kry et al at MD Anderson Cancer
Center23 and Almberg et al at the Norwegian University of Science and Technology25,
out-of-field dose produced by FFF beams was examined using Monte Carlo simulations;
both groups determined that FFF showed clinically relevant reductions in out-of-field
dose when compared with FF beams of similar energy.
Treatment planning studies examining FFF beams in a clinical setting have
been carried out cancers in a variety of sites, including prostate36–38, lung39–41, liver42,43,
and brain44,45. Studies on the effect of FFF-based treatments on spinal column – where
the potential for increased precision from reduction in out-of-field dose, treatment time,
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and head scatter would prove to be of great benefit due to the proximity of tumors to the
spinal cord – are somewhat limited in number and scope. A study by Ong et al conducted
in 2012 investigated the impact of FFF beams compared with FF beams using RapidArc
delivery of SBRT treatments of vertebral bodies in order to determine the effect of the
reduction in treatment time demonstrated by FFF beams on intrafractional shifts46. The
results of the study indicated that dosimetric variations were greater for FFF plans due to
the significantly higher dose rate; however, these results may be complicated by the fact
that the energies examined for each beam – 6 MV for FF and 10 MV for FFF –
introduced differences in the dosimetric properties of each beam such that direct
comparison of the two would be difficult. Additionally, the probability of an
intrafractional shift occurring during a given treatment is lower for FFF beams due to the
much shorter beam-on time, a factor that was not considered by this study. Another
study investigating the effect of FFF beams in IMRT and VMAT treatments of spinal
column metastases where prior radiotherapy had been performed was undertaken by
Dobler et al in 2016 compared target coverage and spinal cord dose between FF and FFF
plans. This study demonstrated significant improvement for FFF beams in normal tissue
sparing and dose homogeneity47. No studies have been found to examine the effect of
FFF beams on minimum dose (Dmin) to the GTV in spine metastases. Due to the limited
number of fractions in SBRT treatments of spine tumors, ensuring that a threshold dose
is met is necessary to ensure that local control is maintained; Bishop et al have found
that Dmin should be at least 14 Gy for single-fraction, 24 Gy plans or at least 21 Gy for
three-fraction, 27 Gy plans to limit the risk of recurrence at follow-up1. The current
study was undertaken to evaluate the effects of FFF beams on GTV Dmin and determine
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the feasibility of using FFF beams in stereotactic radiotherapy for spinal column
metastases.

1.3 – Hypothesis and Specific Aims
We hypothesize that a clinically significant reduction in out-of-field and penumbral
dose such that improved tumor coverage is achieved may be accomplished through the
use of Flattening Filter Free (FFF) photon beams given their unique dosimetric profile
and that FFF beams will generate treatment plans that are clinically equivalent to those
plans developed using FF beams. The hypothesis was tested with the following specific
aims:
1. Examine and characterize the difference in penumbral and peripheral dose
between Flattening Filter Free beams and conventionally flattened beams of similar
depth-dose distributions. This aim shall be done by examining beam profile data for
both FFF and FF beams provided by Varian (Varian Representative Data) as well as
Monte Carlo generated data. The FF beams will be normalized by central axis dose (or
some nominal percentage thereof); the FFF beams will be normalized to 110% at the
central axis for FF profiles and the dose of the FFF profile at the point of 100% dose on
the FF profile in order to account for the different shapes of the two profiles and make a
more fair comparison of peripheral dose. After normalization, we intend to calculate and
compare penumbral widths (the distance between 80%-20% maximum dose) and the
relative dose at varying distances from the field edge (0.5-20 mm from 50% central axis
dose).
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2. Develop and compare treatment plans using FFF and FF beams. This shall be
done using the ECLIPSE treatment planning system and the Varian Representative Data.
We intend to pre-existing plans generated in Pinnacle for 12 unique patients with spinal
metastases, and compare them to plans generated using the Varian Representative Data
for FFF beams. We will be using the Acuros XB Advanced Dose Calculation algorithm
in the ECLIPSE treatment planning system in order to achieve maximum accuracy, as
this project aims to examine high dose gradients, heterogeneities, and out-of-field doses,
all of which are best modeled using Acuros XB. The same dosimetric constraints will be
used to normalize the plans in order to make a fair comparison of the plans. Parameters
to be investigated will include minimum dose to the GTV, D0.03cc to the spinal cord and
cauda equina, beam-on time, and total machine units.

9

2 MATERIALS AND METHODS

2.1 – Analysis of Dose Profiles
2.1.1 – Varian Standard Beam Data
Prior to developing treatment plans, we first analyzed the dose profiles for FF
and FFF beams provided in the Varian Standard Beam Data (Varian Medical Systems
Inc, Palo Alto, CA) - previously the Varian Golden Beam Data - from which we would
be developing beam models for the treatment planning system. The Varian Standard
Beam Data contains Percent Depth Dose (PDD) and dose profile measurements of a
standard Varian TrueBeam for a number of different field sizes and beam energies.
These measurements were taken using an IBA Dosimetry CC13 ionization chamber in a
3D water phantom in step sizes of 1 mm. We compared dose profiles of 6 MV FF and 6
MV FFF beams at depths of 5 cm, 10 cm, 20 cm, and 30 cm and at field sizes of 3x3
cm2, 4x4 cm2, 8x8 cm2, and 10x10 cm2. Penumbral width – defined here as the distance
between the 80% maximum dose point and the 20% maximum dose point – and relative
dose at 2 mm, 5 mm, 10 mm, 30 mm, and 50 mm from the field edge were reviewed.
For this study, absolute difference between penumbral width and penumbral and out-offield dose for FF and FFF beam profiles were assessed and evaluated by Wilcoxon
Signed Rank test.
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2.1.2 – Normalization of Profiles
Due to the difference in shapes between FF and FFF dose profiles, it is
necessary to renormalize each beams in order to make comparison of the penumbral
width more objective. As of this study, there is no standard for this normalization,
though a number of techniques have been used. Pönisch et al. suggested using the
inflection point at the field edge34. This method, though intuitive, has the disadvantage of
introducing a large degree of uncertainty due to the need for incredibly granular
measurements in a high gradient region; often, measurements are taken with no less than
1 mm separation for quality assurance, limiting precision and imposing a minimum
degree of uncertainty into dose profile measurements48. Fogliata et al. favored using a
separate “renormalization point” to determine the normalization factor. A shoulder point
could be found by calculating the third derivative of the FF beam in the penumbra region
and using the second maximum to normalize the FFF beam to the same point48. Since
this study was primarily focused on the effects of the different beams on SBRT
treatments, we elected to normalize FF and FFF beams as described here: FF beams were
normalized such that central axis dose was 110% maximum dose. The location of 100%
maximum dose on the FF profiles was then marked; FFF beams were normalized
according to the relative dose of the FFF beams at that location. This method of
normalization controlled the profile shapes effectively while keeping the dose
distribution within the treatment field within clinically acceptable limits. Figure 2-1
below depicts the two beam profiles before and after normalization.
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Figure 2-1: Dose profiles before and after normalizing. On the left is the raw beam data (normalized to 100% max dose
on the central axis); on the right is the renormalized data (FF normalized to 110% dose, FFF normalized to FFF dose at
location of 100% dose on FF profile).

2.2 – Treatment Planning
2.2.1 – Patient Population
A cohort of 12 patients previously treated for spinal metastases at MDACC
were selected for this study. Of these, four had tumors in the cervical region of the spinal
cord, three in the thoracic region, and five in the lumbar region. Half of these patients
were prescribed 24 Gy in a single fraction by a radiation oncologist; the other half were
prescribed 27 Gy in three fractions. The entire patient population is summarized in Table
2-1 below.
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Table 2-1: Summary of patient population by site, prescription dose, and number of fractions.

Patient
#
1
2
3
4
5
6
7
8
9
10
11
12

Site
L1-L2
T1
L2
T10
L2
L4
C2
C7
C4
T2-T4
C5-C6
L5-S1

Prescription,
Gy
24
24
24
24
24
24
27
27
27
27
27
27

# of
fractions
1
1
1
1
1
1
3
3
3
3
3
3

Epidural spinal cord compression grading (ESCC), also known as the Bilsky
score, was used to determine suitability of patients for SBRT treatment and prescription
dose and normal tissue dose constraints. The Bilsky system defines 6 stages of cord
compression, with Grade 0 defining bone-only disease, Grade 1 defining epidural
impingement (with three stages describing degree of impingement), Grade 2 cord
compression with visible cerebrospinal fluid (CSF) still visible, and Grade 3 cord
compression without visible CSF49. Complete definitions are summarized in Table 2-2
below.
Spine SBRT is recommended for cases with a Bilsky grade of 0-1; higher
Bilsky grades (2-3) are indicative of a need for high caution or unsuitability of SBRT
due to the proximity of the tumor to cord50. Grades 2-3 often require surgical
decompression before SBRT may be considered. Cases where the tumor volume is quite
large or has been previously irradiated are more typically prescribed a higher number of
fractions (27 Gy in 3 fractions versus 24 Gy in a single fraction)50.
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Table 2-2: ESCC/Bilsky Grading Scale

Bilsky Score

Definition

Grade 0
Grade 1a

•

Bone only

•

Epidural impingement, no
deformation of thecal sac
Epidural impingement,
deformation of thecal sac, no
spinal cord abutment
Epidural impingement,
deformation of thecal sac,
spinal cord abutment, no
cord compression
Cord compression with
visible cerebrospinal fluid
(CSF) around cord
Cord compression without
visible CSF around spinal
cord

•
Grade 1b
•
Grade 1 c
•
Grade 2
•
Grade 3

GTV volume for each patient is summarized below; average volume for all twelve
patients was 21.10 cm3 and ranged from 10.3 cc (Patient 8) to 100.7 cc (Patient 6).
Table 2-3: GTV Volume (cm3)

Patient
ID

GTV
Volume (cc)

24 Gy Single-Fraction
1
53.2
2
11.1
3
50.1
4
19.7
5
42.5
6
100.7
27 Gy Three-Fraction
7
22.5
8
10.3
9
14.6
10
62.7
11
11.1
12
10.5
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2.2.2 – Treatment Planning Parameters
For each patient, two treatment plans were developed: one using 6 MV FF
beam data and the other using 6 MV FFF beam data. The dose rate was set to 600
MU/min for FF plans; for FFF plans, the dose rate was 1400 MU/min. The maximum
dose rate was chosen for FFF plans in order to take advantage of the potential reduction
of beam-on time and resultant lowered integral dose20. For each plan, identical beam
arrangements were used: for the majority of plans, nine coplaner beams spaced 20° apart
from 100° to 260° were defined in the treatment planning system (TPS). Figure 2-2
shows a representative plan. Three patients (Patient 1, Patient 8, and Patient 11) did not
have this arrangement due to the location of the gross tumor volume relative to the
respective organs at risk. Multiple Static Segments using 10 segments per field were
used for plan delivery.

Figure 2-2: Standard beam arrangement for spinal SBRT patients
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All treatment plans were generated using the Eclipse TPS and the Acuros XB
dose calculation algorithm (Varian Medical Systems, Palo Alto, CA). Eclipse was
chosen as the TPS for this study due to the demonstrated ability for Acuros XB – a
dose calculation algorithm exclusive to Eclipse that utilizes the Linear Boltzmann
Transport Equation - to accurately account for tissue heterogeneities including FFF
beams as well as FF beams51,52.

For all patients, plans were developed with the goal of increasing minimum
dose to the GTV Dmin up to and beyond the recommended threshold for the
prescription without pushing dose to normal tissue and primary organs at risk (OAR)
above acceptable levels. For patients receiving 24 Gy in a single fraction, a Dmin of
at least 14 Gy was attempted; for patients receiving 27 Gy in three fractions, the goal
was a Dmin of at least 21 Gy. These planning directives were used to maintain
efficacy of the plans, as doses lower than 14 Gy (single fraction) or 21 Gy (three
fraction) were found to be associated with decreased local control1. To improve
comparison between the two sets of plans, dose to the cauda equina (lumbar patients)
or spinal cord (cervical and thoracic patients) was kept within 5% between FF and
FFF plans.
All patients were originally treated at MD Anderson using plans developed in
the Pinnacle TPS. Plans created for this study utilized the plans, physician planning
directives, and institutional guidelines (Table 2-2 below) to determine normal tissue
tolerance and field arrangement. Dmax to the spinal cord was kept below 10 Gy for
all plans regardless of prescription; Dmax to the cauda equina was kept below 16 Gy
16

or 14 Gy for single- and three-fraction courses, respectively. As most patients had
received prior irradiation, more conservative dose guidelines were utilized; this
limited how much dose could be delivered to the target volume, but was necessary to
limit late effects of radiation on normal tissue volumes had the patients been treated
with these plans.
Table 2-4: Institutional Guidelines for Normal Tissue Tolerances

Single Fraction

Three Fraction

Organ

Volume Dose

Maximum
Dose

Volume Dose

Maximum
Dose

Spinal Cord

V(8Gy) ≤ 1cc

10 Gy

V(9Gy) ≤ 0.01cc

10 Gy

Cauda Equina

V(10Gy) ≤ 1cc

16 Gy

V(12Gy) ≤ 0.1cc

14 Gy

Esophagus

V(12Gy) ≤ 5cc

16 Gy

V(12Gy) ≤ 5cc

16 Gy

Brachial Plexus

V(11.9Gy) ≤ 3cc

16 Gy

V(15Gy) ≤ 0.01cc

17 Gy

Heart

V(16Gy) ≤ 15cc

22 Gy

V(15Gy) ≤ 15cc

21 Gy

Trachea

V(8.8Gy) ≤ 4cc

20.2 Gy

V(8.8Gy) ≤ 4cc

18 Gy

Skin

V(14Gy) ≤ 10cc

16 Gy

V(16Gy) ≤ 10cc

21 Gy

Small Bowel

V(9Gy) ≤ 5cc

15.4 Gy

V(9Gy) ≤ 0.01cc

10 Gy

Colon

V(11Gy) ≤ 20cc

18.4 Gy

V(11Gy) ≤ 20cc

18 Gy

Rectum

V(11Gy) ≤ 20cc

18.4 Gy

V(11Gy) ≤ 20cc

18 Gy

Each Kidney

V(8Gy) ≤ 2/3 Volume

N/A

V(10Gy) ≤ 4/5 Volume

N/A

Total Kidney

V(8.4Gy) ≤ 200cc,
V(7.4Gy) ≤ 1000cc

N/A

V(10Gy) ≤ 1/5 Volume

N/A

Total Lung

V(7Gy) ≤ 1000cc

N/A

V(10Gy) ≤ 600cc

N/A

Other

Volume outside PTV(≥100110% Prescription) ≤ 1cc

N/A

Volume outside PTV(≥100110% Prescription) ≤ 8cc

N/A

Order of plan creation was alternated for each patient such that biases by the
primary planner were limited – for example, if Patient 1’s planning order was FF
followed by FFF, then Patient 2’s planning order was FFF followed by FF.
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2.3 – Statistical Analysis
We applied Wilcoxon signed rank test to compare the dose profiles for FF and
FFF beams and GTV Dmin between the treatment plans. A two-sided p-value of less
than 0.05 was considered statistically significant. All analyses were performed with
statistical software R v3.4.3 (Vienna, Austria 2016).
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3 RESULTS

3.1 – Analysis of Dose Profiles
3.1.1 – Penumbral Dose
Relative dose in the penumbra was compared between FF and FFF plans at
distances of 2 mm, 5 mm, 10 mm, 30 mm, and 50 mm from the field edge at depths of
5 cm, 10 cm, 20 cm, and 30 cm at four depths and for five different field sizes. The
percent difference between FFF and FF was calculated and plotted at 5 cm, 10 cm, 20
cm, and 30 cm depths, shown respectively in Figures 3-1 thru 3-4.
The ratio of FFF dose to FF dose ranged from 0.72 to 1.06 with a mean of
0.971 and a standard deviation of 0.05. The reduction in penumbral dose was found to
be significant by Wilcoxon Signed Rank Test (p < 0.05).
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Figure 3-1: FF (solid lines) and FFF (dashed lines) penumbral dose at 5 cm depth
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Figure 3-2: FF (solid lines) and FFF (dashed lines) penumbral dose at 10 cm depth
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Figure 3-3: FF (solid lines) and FFF (dashed lines) penumbral dose at 20 cm depth
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Figure 3-4: FF (solid lines) and FFF (dashed lines) penumbral dose at 30 cm depth

FFF profiles tended to have lower relative penumbral dose compared to FF
profiles. This finding was particularly pronounced with smaller field sizes, as the
reduction tended to be reduced (and, at greater depths, reversed) as field size
increased.
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Figure 3-5: Close up of penumbral doses of FFF and FF beams at 5 cm depth.
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9

9.5

10

Figure 3-5 (above) shows the region where the difference between FF and FFF was
largest for all field sizes at 5 cm depth; this difference was greatest between 5-10 mm
from the field edge.
3.1.2 – Penumbral Width
There was an overall decrease in width for FFF beams when compared with
FF beams for all depths and field sizes with the exception of the 10x10 cm2 field for both
20 cm depth and 30 cm depth. Reduction in penumbral width ranged from 0.77% to 5.02%.
Although there was no significant difference in penumbral width within each individual field
size, the overall reduction in width for all field sizes and depths was significant by Wilcoxon
signed rank test (p < 0.05). The reduced dose and sharpened penumbra associated with FFF

beams for fields relevant to spine SBRT treatments motivated continuation with the
treatment planning to determine the practical effect of reduced penumbral width on our
patient population.

Table 3-1: Difference (mm) in penumbral width of FFF beams relative to FF beams in water at various depths (cm)

Depth in Water Phantom
Field Size (cm2)

5

10

20

30

p-value

3x3

-0.16

-0.11

-0.27

-0.19

0.0625

4x4

-0.10

-0.22

-0.14

-0.13

0.0625

6x6

-0.16

-0.21

-0.15

-0.23

0.0625

8x8

-0.20

-0.12

-0.10

-0.07

0.0625

10x10

-0.23

-0.04

0.04

0.22

0.563

22

3.2 – Comparison of Treatment Plans
Dmin for the GTV for each treatment plan was compared between FF and FFF
plans. The DVH median and interquartile range were calculated and plotted for singleand three-fraction plans (Figure 3-6 A, B). Median dose was higher for FFF plans in the
single-fraction set (Figure 3-6A) and lower for FFF plans in the three-fraction set (Figure
3-6B); however, overall differences were not statistically significant.
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Figure 3-6: Median DVHs for single-and three-fraction GTV
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Median DVHs were also calculated and plotted for spinal cord (Figure 37A) and cauda equina (Figure 3-7B). This analysis was performed to ensure that
there was no significant difference in OAR dose in order to better compare GTV
Dmin for each plan. The median dose was nearly identical at all points of the
DVH for both cauda equina and spinal cord. Interquartile spread was quite wide
for the cauda equina DVH; however, this finding is attributed to the fact that the
cauda equina was the primary OAR for both single- and three-fraction plans, for
which the max dose limit differed by 2 Gy (16 Gy and 14 Gy for single- and
three-fraction plans, respectively). The spinal cord DVH interquartile spread was
tighter, as maximum cord dose was the same regardless of fraction number.
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Figure 3-7: Cauda and Cord Median DVH
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GTV Dmin was calculated and compared for both FF and FFF plans. Six of
the twelve plans demonstrated an increase in Dmin for FFF plans. The increase in
Dmin dose was not found to be significant by Wilcoxon Signed Rank Test (p = 0.17).
The results are summarized below in Table 3-2.

Table 3-2: GTV Dmin for FF and FFF Plans

Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
Patient 7
Patient 8
Patient 9
Patient 10
Patient 11
Patient 12

Minimum GTV Dose
FF
FFF
24 Gy Single-Fraction
11.98
10.81
10.34
10.63
15.78
15.81
10.73
10.31
22.45
21.07
13.82
14.15
27 Gy Three-Fraction
7.30
8.43
16.49
15.73
9.05
8.93
9.73
9.28
8.16
8.19
20.84
21.89
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% Difference
10.21%
2.73%
0.21%
3.91%
6.35%
2.34%
14.46%
4.73%
1.33%
4.75%
0.35%
4.90%

OAR0.03cc was also calculated for each plan to ensure that dose for the spinal cord or
cauda was within 5% for FF and FFF plans. The results are listed below in Table 3-4. It
is worth noting that although these were the primary OAR, the cord and/or cauda equina
did not define the end-point of planning. All normal tissue limits were observed. As
such, planning was often considered complete not when maximum primary OAR dose
was met, but when other normal tissue began to exceed dose constraints, leading to a
lower than expected GTV dose.
Table 3-3: OAR0.03cc

OAR0.03cc

Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
Patient 7
Patient 8
Patient 9
Patient 10
Patient 11
Patient 12

Primary
FF
FFF
OAR
24 Gy Single-Fraction
Cauda
12.6
12.1
Cord
7.4
7.6
Cauda
12.6
12
Cord
7.7
7.6
Cauda
15.2
15.1
Cauda
13.7
14.2
27 Gy Three-Fraction
Cord
5.95
5.7
Cord
5.6
5.8
Cord
7.95
8
Cord
8.8
8.6
Cord
7.4
7.45
Cauda
6.4
6.45

% Difference
4.05%
2.67%
4.88%
1.31%
0.66%
3.58%
4.29%
0.00%
0.63%
2.30%
0.67%
0.00%

Beam-on time was also evaluated for each plan, as the duration of treatment
may have an effect on integral dose. Namely, shorter treatment times limit the potential
for intrafractional error due to patient motion. Beam on-time per fraction was calculated
as the dividend of total MU divided by the dose rate (600 MU/minute for FF, 1400
MU/minute for FFF). Treatment duration was definitively lower for FFF plans compared
with FF plans (p-value < 0.05). The average reduction in beam-on time was 12.5
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minutes, with the largest difference being a reduction of 27.8 minutes (Patient 6) and the
smallest being a reduction of 1.73 minutes (Patient 11). The beam-on time per fraction is
summarized below in Table 3-5.

Table 3-4: Beam-on time per fraction

Beam-on Time
FF
24 Gy Single-Fraction
Patient 1
23.16
Patient 2
23.26
Patient 3
47.29
Patient 4
44.47
Patient 5
21.49
Patient 6
42.52
27 Gy Three-Fraction
Patient 7
9.54
Patient 8
10.78
Patient 9
5.52
Patient 10
22.64
Patient 11
8.84
Patient 12
11.64
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FFF
15.39
9.48
19.58
19.85
9.84
14.74
3.8
5.12
2.57
12.08
7.11
1.98

Total MUs for each patient plan were calculated and have been recorded below in
Table 3-6.

Table 3-5: Total MUs for each patient plan

Total MUs
Patient
FF
FFF
ID
24 Gy Single-Fraction
1
13896
21543
2
13958
13278
3
28372
27418
4
26682
27789
5
12893
13782
6
25512
20638
27 Gy Three-Fraction
7
17175
15945
8
19398
21507
9
9939
28788
10
40746
50733
11
15909
29841
12
20943
8328
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Grid size for each patient was the same for both FF and FFF plans and was scaled
such that the dose calculated included the entire scanned patient volume. Grid resolution
was 2.5 mm for all patients and plans. Grid sizes for each patient is listed below in Table
3-6.

Table 3-6: Dose grid size (pixels)

Patient ID
1
2
3
4
5
6
7
8
9
10
11
12

Size (Pixel)
Width Height
149
100
220
113
143
108
146
98
147
97
138
103
167
96
181
111
199
113
217
111
210
107
138
96
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Heterogeneity index (HI) was calculated for each plan as the ratio of highest dose
received by 5% of the PTV to lowest dose received by 95% of the PTV53 and is shown
below in Table 3-7.

Table 3-7: Heterogeneity Index for all plans

Heterogeneity Index
Patient ID FF
FFF
1
1.57 1.96
2
1.65 1.63
3
2.03 1.83
4
2.01 1.85
5
1.51 1.78
6
1.59 1.63
7
1.74 1.71
8
1.58 1.53
9
2.13 2.18
10
1.92 2.07
11
1.91 1.93
12
1.41 1.39
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Field size varied and was dependent on the size of the CTV. Jaws were
collimated such that there was a 5 mm margin around the CTV on all sides. Average
field size for each plan is summarized below.

Table 3-8: Average field sizes (cm)

Patient ID
1
2
3
4
5
6
7
8
9
10
11
12

Average Field Size
FF
FFF
X
Y
X
Y
10.1
9.9
10.2
10.0
8.6
4.6
8.0
4.5
6.6
6.2
6.4
6.2
6.4
3.6
6.2
8.0
10.0
13.0
6.4
4.6
10.5
5.0
10.4
5.1
7.3
4.4
7.1
4.5
4.4
3.9
4.4
3.9
8.3
3.8
8.3
3.8
8.3
8.8
7.9
8.9
5.7
5.5
5.4
4.9
9.2
6.8
9.1
6.8
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4 DISCUSSION

4.1 – General Discussion
We compared penumbral width as well as penumbral and out-of-field dose for FF
and FFF beams using dose profiles obtained in a 3D water phantom from the Varian
Standard Beam Data. Our results indicate that there is a statistically significant (p < 0.05)
difference between FF and FFF beams in penumbral width and dose. This reduction
tended to be more exaggerated at smaller field sizes and at shallower depths with larger
field sizes tending towards increased penumbral dose and width for FFF beams
compared with FF beams. That smaller field sizes tend to show more benefit from FFF
beams is notable, as the trend towards highly-modulated treatment techniques (IMRT
and SBRT) translates to field sizes overall growing smaller. This potential for reduction
in normal tissue dose is an important factor to be considered in treatment planning,
particularly for targets in close proximity to critical OAR.
It is important to note, however, that the absolute difference in penumbral width
was quite small. At no field size or depth did the difference exceed 0.3 mm. This
observation suggests that the clinical benefits of FFF over FF, with respect to dose fall
off, may in fact be quite minimal. Additionally, the difference in penumbral dose
determined here represents only the difference in dose relative to the central axis at five
points (2 mm, 5 mm, 10 mm, 30 mm, and 50 mm from the field edge). As such, the
actual reduction in penumbral dose may be even smaller.

34

Treatment plans utilizing both FF and FFF beams were developed for 12 patients
with spinal metastases in the cervical, thoracic, and lumbar regions. For each patient
GTV Dmin was extracted and compared between the FF and FFF plans. Improvement in
GTV Dmin was seen in approximately half of the patients while the other half saw either
no improvement or a reduction in Dmin. The overall difference in GTV Dmin was
deemed to be statistically insignificant by Wilcoxon Signed Rank Test.
The differences in treatment delivery time are pronounced in that FFF plans had
overall shorter beam on times compared with FF plans in all but a single case (Patient
12). The potential benefit of this outcome for patients cannot be overstated, as patients
with spinal metastases often present with pain and motor dysfunction and find it difficult
to lie still on the treatment couch during delivery, introducing a greater potential for
intrafractional variation. Shorter treatment times limit that potential and improve patient
experience and throughput
One should note that the results of a treatment planning study may be confounded
by several factors. Experience and ability of the planner, planning system and dose
algorithm used, beam model, optimization parameters, beam configuration, planning
objectives, patient positioning, segment number, time spent planning, number of
iterations, and gross anatomy may all contribute to the quality of the plan. These factors
make achieving a completely objective plan comparison quite difficult, as a different
planner may create entirely different plans with the same patient population and achieve
different results.
A potential limiting factor of this study is the method in which the beam models
were generated and the dose calculation algorithm that was used. The Varian Standard
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Beam Data, from which the beam models were generated in Eclipse, were obtained using
an ionization chamber – the poor spatial resolution inherent to this measurement in
addition to the high dose gradient of the primary region of interest (i.e., the penumbra)
may have a negative effect on the beam model, making accurate dose calculation
difficult. Additionally, Acuros XB dose calculation algorithm used for this study, while
generally quite accurate, is not as precise or accurate as a dose calculation made using
Monte Carlo methods would be. As such, it is possible that any demonstrable differences
between FF and FFF plans may have been confounded by these factors.

4.2 – Conclusions
In conclusion, the hypothesis that the use of FFF beams in SBRT treatments of
spinal cord metastases would improve target coverage was not entirely supported. Half
of the patients saw some benefit from FFF in terms of increased GTV Dmin, but half did
not. Although there was a statistically significant reduction in penumbral width and dose
for FFF beams when compared with FF beams, this difference was in absolute terms
quite minute. All but one patient had shorter beam-on times with FFF beams compared
to FF beams. Treatment plans developed for patients with spinal metastases using FFF
beams were equivalent to those developed using traditional FF beams when dose to the
spinal cord or cauda equina was kept within 5% between FF and FFF plans.
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4.3 – Future Work
As half of the patients had improved GTV Dmin and all but one had reduced delivery
times with plans generated using FFF beams, it is possible that certain specific patients
derive more benefits from FFF over others. Future work on this project will likely
include multivariate analysis on a much larger patient population in order to determine
what factors would indicate that a patient would be better served with a plan generated
using FFF. Factors that would be investigated may include tumor size, shape, location,
pathology, patient anatomy, treatment history, etc.
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5 APPENDIX
5.1 – Individual Patient Plans

Figure 5-1: Patient 1 axial isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-2: Patient 1 coronal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-3: Patient 1 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-4: Patient 1 DVH
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Figure 5-5: Patient 2 axial isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-6: Patient 2 coronal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-7: Patient 2 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-8: Patient 2 DVH
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Figure 5-9: Patient 3 axial isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-10: Patient 3 coronal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-11: Patient 3 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-12: Patient 3 DVH
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Figure 5-13: Patient 4 axial isodose images. Top: FF Plan, Bottom: FFF Plan, Bottom: Plan
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Figure 5-14: Patient 4 coronal isodose images. Top: FF Plan, Bottom: FFF Plan, Bottom: Plan
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Figure 5-15: Patient 4 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-16: Patient 4 DVH
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Figure 5-17: Patient 5 axial isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-18: Patient 5 coronal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-19: Patient 5 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-20: Patient 5 DVH
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Figure 5-21: Patient 6 axial isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-22: Patient 6 coronal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-23: Patient 6 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-24: Patient 6 DVH
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Figure 5-25: Patient 7 axial isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-26: Patient 7 coronal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-27: Patient 7 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-28: Patient 7 DVH
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Figure 5-29: Patient 8 axial isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-30: Patient 8 coronal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-31: Patient 8 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-32: Patient 8 DVH
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Figure 5-33: Patient 9 axial isodose images. Top: FF Plan, Bottom: FFF Plan, Bottom: Plan

70

Figure 5-34: Patient 9 coronal isodose images. Top: FF Plan, Bottom: FFF Plan, Bottom: Plan
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Figure 5-35: Patient 9 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan, Bottom: Plan
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Figure 5-36: Patient 9 DVH
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Figure 5-37: Patient 10 axial isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-38: Patient 10 coronal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-39: Patient 10 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-40: Patient 10 DVH
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Figure 5-41: Patient 11 axial isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-42: Patient 11 coronal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-43: Patient 11 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-44: Patient 11 DVH
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Figure 5-45: Patient 12 axial isodose images. Top: FF Plan, Bottom: FFF Plan, Bottom: Plan
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Figure 5-46: Patient 12 coronal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-47: Patient 12 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan
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Figure 5-48: Patient 12 DVH
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5.2 – Dose to Water vs. Dose to Medium
Dose was calculated as dose to medium rather than dose to water; it should be noted
that there exist minor differences between these two calculation methods, as
demonstrated below in Figure 2-3. The difference between dose to medium and dose to
water has been shown to differ by as little as 1.0% for soft tissue and 10% for cortical
bone54. Dose to water has been the historical method of dose calculation due to how
linacs are typically calibrated; nevertheless, accurate methods of computing absorbed
dose to medium offer a more realistic view of how dose is deposited in the patient.
Therefore, we chose to forego dose to water calculation and instead used dose to medium
for this study.

Figure 5-49: DVH for Dose to Medium vs. Dose to Water. Dose to Water is indicated with triangles; dose to medium with
squares. Magenta, yellow, and red represent cauda equina, CTV, and GTV, respectively.
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